EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia

Atsushi Kohso, Hidemi Toyoda, Ryo Hanaki, Kaori Niwa, Yosuke Okumura, Mari Morimoto, Takahiro Ito, Masahiro Hirayama

International Journal of Hematology · 2025

DOI: 10.1007/s12185-024-03890-1 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Hematology, 2025. Verfasst von Atsushi Kohso und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. Hauptthemen laut MEDLINE: Down Syndrome, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inotuzumab ozogamicin (InO), a CD22-directed antibody conjugated to calicheamicin, has demonstrated excellent efficacy in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). It has been used for patients with relapsed or refractory BCP-ALL as a bridge to allo-HCT. Children with Down syndrome (DS) have an increased risk of BCP-ALL and higher rates of relapse and toxicity, including treatment-related mortality. Although allo-HCT is potentially curative for relapsed or refractory ALL, post-transplant leukemic relapse rates and transplant-related mortality are dismal in patients with DS-ALL, which results in less frequent use of allo-HCT in this group than in the non-DS population. Therefore, novel and less toxic therapeutic strategies are required to improve outcomes. Here we report the case of a child with DS who was diagnosed with a second relapse of BCP-ALL and has maintained complete remission through regular single-agent InO therapy. Single-agent maintenance using InO can be a good option to avoid subsequent relapse in patients with relapsed or refractory BCP-ALL who cannot proceed to allo-HCT and require less-toxic treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromePrecursor Cell Lymphoblastic Leukemia-LymphomaAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalHumansInotuzumab OzogamicinMaleSecondary PreventionRecurrenceHematopoietic Stem Cell TransplantationChild

Stichwörter der Autor:innen

B-cell precursor acute lymphoblastic leukemiaInotuzumab ozogamicinMaintenance chemotherapyRelapse

Substanzen

Inotuzumab OzogamicinAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Pediatrics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
  • Department of Pediatrics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. htoyoda@med.mie-u.ac.jp.

Zitieren

APA

Kohso, A., Toyoda, H., Hanaki, R., Niwa, K., Okumura, Y., Morimoto, M., Ito, T., & Hirayama, M. (2025). Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03890-1

Vancouver

Kohso A, Toyoda H, Hanaki R, Niwa K, Okumura Y, Morimoto M, et al. Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia. International Journal of Hematology. 2025. doi:10.1007/s12185-024-03890-1

BibTeX
@article{Kohso2025,
  author = {Kohso, Atsushi and Toyoda, Hidemi and Hanaki, Ryo and Niwa, Kaori and Okumura, Yosuke and Morimoto, Mari and Ito, Takahiro and Hirayama, Masahiro},
  title = {Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia},
  journal = {International Journal of Hematology},
  year = {2025},
  doi = {10.1007/s12185-024-03890-1}
}
Kostenlos starten →